CN1906189A - 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物 - Google Patents

用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物 Download PDF

Info

Publication number
CN1906189A
CN1906189A CNA2004800409412A CN200480040941A CN1906189A CN 1906189 A CN1906189 A CN 1906189A CN A2004800409412 A CNA2004800409412 A CN A2004800409412A CN 200480040941 A CN200480040941 A CN 200480040941A CN 1906189 A CN1906189 A CN 1906189A
Authority
CN
China
Prior art keywords
acetate
alkyl
phenyl
methyl
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800409412A
Other languages
English (en)
Chinese (zh)
Inventor
罗杰·V·邦纳特
拉克萨纳·T·莫哈迈德
西蒙·蒂格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1906189A publication Critical patent/CN1906189A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800409412A 2003-11-26 2004-11-24 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物 Pending CN1906189A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE03031804 2003-11-26
SE0303180A SE0303180D0 (sv) 2003-11-26 2003-11-26 Novel compounds

Publications (1)

Publication Number Publication Date
CN1906189A true CN1906189A (zh) 2007-01-31

Family

ID=29729190

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800409412A Pending CN1906189A (zh) 2003-11-26 2004-11-24 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物

Country Status (6)

Country Link
US (1) US20080027092A1 (https=)
EP (1) EP1699781A1 (https=)
JP (1) JP2007512299A (https=)
CN (1) CN1906189A (https=)
SE (1) SE0303180D0 (https=)
WO (1) WO2005054232A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892288A (zh) * 2010-02-11 2013-01-23 范德比尔特大学 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
CA2558545C (en) * 2004-03-11 2012-10-16 Actelion Pharmaceuticals Ltd Indol-1-yl-acetic acid derivatives
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422830A (en) * 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
TW200720255A (en) * 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP5064219B2 (ja) * 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
CN101454284A (zh) * 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
BRPI0715179A2 (pt) 2006-08-07 2013-06-11 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2265581A1 (en) * 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
US8124641B2 (en) 2008-07-15 2012-02-28 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
CA2730390A1 (en) * 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
WO2010018109A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Substituted aminotetralines
CA2735392A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
US8188090B2 (en) 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
DK2346819T3 (da) 2008-11-17 2013-05-13 Hoffmann La Roche Naphthyleddikesyre
JP2012508715A (ja) 2008-11-17 2012-04-12 エフ．ホフマン−ラ ロシュ アーゲー ナフチル酢酸
AU2009322836B2 (en) * 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JPWO2010087425A1 (ja) * 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
PT2558447E (pt) 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9hcarbazol e o seu uso como moduladores do receptor de prostaglandina d2
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CA2867901A1 (en) 2012-03-21 2013-09-26 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
ES2947824T3 (es) 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
TW201819361A (zh) * 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
CN108586311B (zh) * 2018-03-23 2020-05-26 温州医科大学 一种3-硫醚吲哚或3-硒醚吲哚的制备方法
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPS5944312B2 (ja) * 1974-11-22 1984-10-29 中外製薬株式会社 インダゾ−ル誘導体の製法
JPH0615542B2 (ja) * 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
JPH06206872A (ja) * 1992-10-06 1994-07-26 Yoshitomi Pharmaceut Ind Ltd 縮合型ピラゾール化合物
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
SK1182002A3 (en) 1999-07-28 2002-11-06 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
OA12514A (en) * 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US6506738B1 (en) * 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
CN101454284A (zh) * 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892288A (zh) * 2010-02-11 2013-01-23 范德比尔特大学 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法
CN102892288B (zh) * 2010-02-11 2016-02-24 范德比尔特大学 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法

Also Published As

Publication number Publication date
JP2007512299A (ja) 2007-05-17
WO2005054232A1 (en) 2005-06-16
US20080027092A1 (en) 2008-01-31
SE0303180D0 (sv) 2003-11-26
EP1699781A1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
CN1906189A (zh) 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物
CN1795174A (zh) 新型取代的3－硫吲哚
CN1279023C (zh) 吲哚－3－硫衍生物
CN1148189C (zh) 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物
CN1072220C (zh) 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
CN1310907C (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1784402A (zh) 用作jak3激酶抑制剂的咪唑并和噻唑并吡啶化合物
CN101035774A (zh) 用于治疗前列腺素d2介导的疾病的crth2受体活性调节剂
CN1671659A (zh) 新的取代吲哚
CN1046725C (zh) 稠合的咪唑化合物,它们的制备和应用
CN101035785A (zh) 具有抗菌活性的新化合物
CN1922161A (zh) 1－哌嗪－和1－高哌嗪－羧酸酯衍生物、制备和其治疗用途
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1127486C (zh) 二氮杂萘衍生物磷酸二酯酶4抑制剂
CN1310890C (zh) 异喹啉衍生物
CN1829694A (zh) 喹啉衍生物和它们在治疗中的用途
CN87103504A (zh) 杂环羧酰胺
CN101048369A (zh) 用于治疗呼吸系统疾病的联苯基氧基乙酸衍生物
CN1035255C (zh) 杂三环衍生物
CN1011780B (zh) 苯氧基乙酸衍生物的制备方法
CN1589261A (zh) 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途
CN101056871A (zh) 作为血管内皮生长因子（vegf）受体激酶抑制剂的新的邻氨基苯甲酰胺吡啶脲
CN1022322C (zh) 稠合吡唑3-氧代-丙腈衍生物的制备方法
CN1148355C (zh) 哒嗪-3-酮衍生物和含有该类化合物的药物
CN1735618A (zh) 用作ltd4拮抗剂的新型三环衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070131